bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Materials and Methods from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure. S5 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

DHT upregulation of GRM1 expression is AR-dependent.
Supplementary Figure. S4 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

GRM1 expression in parental and stable transfectants using anti-Myc antibody.
Supplemental Figures from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Authors: Dickler Maura N. , Tolaney Sara M. , Rugo Hope S. , Cortés Javier , Diéras Véronique , Patt Debra , Wildiers Hans , Hudis Clifford A. , O'Shaughnessy Joyce , Zamora Esther , Yardley Denise A. , Frenzel Martin , Koustenis Andrew , Baselga José
Published: April 2023

Supplemental Figure 1. Study Design and Patient Disposition Supplemental Figure 2. Change in serum creatinine by visit Supplemental Figure 3. Change in blood urea nitrogen (BUN) by visit Supplemental Figure 4. Maximum observed value in cystatin C by visit Supplemental Figure 5. Minimum Observed Value in Neutrophils by Visit
Supplemental Table 3 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Authors: Assadipour Yasmine , Zacharakis Nikolaos , Crystal Jessica S. , Prickett Todd D. , Gartner Jared J. , Somerville Robert P.T. , Xu Hui , Black Mary A. , Jia Li , Chinnasamy Harshini , Kriley Isaac , Lu Lily , Wunderlich John R. , Zheng Zhili , Lu Yong-Chen , Robbins Paul F. , Rosenberg Steven A. , Goff Stephanie L. , Feldman Steven A.
Published: April 2023

Mutation expression in metastatic lesions at autopsy.
Supplemental Figure 3 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Authors: Assadipour Yasmine , Zacharakis Nikolaos , Crystal Jessica S. , Prickett Todd D. , Gartner Jared J. , Somerville Robert P.T. , Xu Hui , Black Mary A. , Jia Li , Chinnasamy Harshini , Kriley Isaac , Lu Lily , Wunderlich John R. , Zheng Zhili , Lu Yong-Chen , Robbins Paul F. , Rosenberg Steven A. , Goff Stephanie L. , Feldman Steven A.
Published: April 2023

Clonal architecture of 4062 tumor.
Supplemental Figure 1 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Authors: Assadipour Yasmine , Zacharakis Nikolaos , Crystal Jessica S. , Prickett Todd D. , Gartner Jared J. , Somerville Robert P.T. , Xu Hui , Black Mary A. , Jia Li , Chinnasamy Harshini , Kriley Isaac , Lu Lily , Wunderlich John R. , Zheng Zhili , Lu Yong-Chen , Robbins Paul F. , Rosenberg Steven A. , Goff Stephanie L. , Feldman Steven A.
Published: April 2023

Recognition of mRNA-encoded RBPJ mutation.
Supplementary Data from The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity
Authors: Digomann David , Kurth Ina , Tyutyunnykova Anna , Chen Oleg , Löck Steffen , Gorodetska Ielizaveta , Peitzsch Claudia , Skvortsova Ira-Ida , Negro Giulia , Aschenbrenner Bertram , Eisenhofer Graeme , Richter Susan , Heiden Stephan , Porrmann Joseph , Klink Barbara , Schwager Christian , Dowle Adam A. , Hein Linda , Kunz-Schughart Leoni A. , Abdollahi Amir , Lohaus Fabian , Krause Mechthild , Baumann Michael , Linge Annett , Dubrovska Anna
Published: April 2023

Supplementary discussion; Supplementary methods; Supplementary tables S1-S8; Supplementary figures S1-S8.
Sup Tables 1-6 from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Authors: Pandzic Tatjana , Larsson Jimmy , He Liqun , Kundu Snehangshu , Ban Kenneth , Akhtar-Ali Muhammad , Hellström Anders R. , Schuh Anna , Clifford Ruth , Blakemore Stuart J. , Strefford Jonathan C. , Baumann Tycho , Lopez-Guillermo Armando , Campo Elias , Ljungström Viktor , Mansouri Larry , Rosenquist Richard , Sjöblom Tobias , Hellström Mats
Published: April 2023

Supplementary Table S1. 782 genes identified by piggyBac transposon mutagensis in HG3 cell line after fludarabine selection Supplementary Table S2. Gene Symbol/Gene Description Supplementary Table S3A. Molecular characteristics of BRAF mutant cases in the Spanish cohort. Supplementary Table S3B. Molecular characteristics of BRAF mutant cases in the UK LRF CLL4 cohort. Supplementary TableS 4. Genes differentially regulated in HG3 cells after fludarabine selection. Supplementary Table S5. Gene Set Name [# Genes (K)] Supplementary Table S6. Distribution of mutations in the BRAF gene in CLL.
Figure S1, Figure S2, Figure S3, Table S1, Table S2, Table S3, Table S4 and Table S5 from Clonotypic Diversity of the T-cell Receptor Corroborates the Immature Precursor Origin of Cutaneous T-cell Lymphoma
Authors: Hamrouni Abdelbasset , Fogh Hanne , Zak Zoulika , Ødum Niels , Gniadecki Robert
Published: April 2023

Figure S1 shows distribution of the most abundant TCR clonotypes in MF compared to inflammatory infiltrates. Figure S2 shows detailed analysis of the TCR repertoire using VDJtools sofware. Figure S3 shows examples of stained skin sections used for LCM. Table S1 shows efficiency of our NGS protocol for the first set of MF samples. Table S2 shows detection of the TCR rearrangements in microdissected MF samples. Table S3 shows sequences of the oligonucleotide primers. Table S4 shows data from spiked-in experiment of MyLa cells in PBMCs from a healthy donor. Table S5 shows results of single-cell analysis of TCRγ rearrangements in MF samples.
Supplementary Tables S1-S8 from Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions
Authors: Pisanic Thomas R. , Cope Leslie M. , Lin Shiou-Fu , Yen Ting-Tai , Athamanolap Pornpat , Asaka Ryoichi , Nakayama Kentaro , Fader Amanda N. , Wang Tza-Huei , Shih Ie-Ming , Wang Tian-Li
Published: April 2023

Supplementary Tables S1-S8
Supplementary Figure 3 from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Authors: Mateo Joaquin , Ganji Gopinath , Lemech Charlotte , Burris Howard A. , Han Sae-Won , Swales Karen , Decordova Shaun , DeYoung M. Phillip , Smith Deborah A. , Kalyana-Sundaram Shanker , Wu Jiuhua , Motwani Monica , Kumar Rakesh , Tolson Jerry M. , Rha Sun Young , Chung Hyun Cheol , Eder Joseph P. , Sharma Sunil , Bang Yung-Jue , Infante Jeffrey R. , Yan Li , de Bono Johann S. , Arkenau Hendrik-Tobias
Published: April 2023

Supplementary Figure 3: Glucose and insulin levels after treatment with GSK2636771 in fasted mice.
Supplementary Figure 2 from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Authors: Mateo Joaquin , Ganji Gopinath , Lemech Charlotte , Burris Howard A. , Han Sae-Won , Swales Karen , Decordova Shaun , DeYoung M. Phillip , Smith Deborah A. , Kalyana-Sundaram Shanker , Wu Jiuhua , Motwani Monica , Kumar Rakesh , Tolson Jerry M. , Rha Sun Young , Chung Hyun Cheol , Eder Joseph P. , Sharma Sunil , Bang Yung-Jue , Infante Jeffrey R. , Yan Li , de Bono Johann S. , Arkenau Hendrik-Tobias
Published: April 2023

Supplementary Figure 2: LNCAP and DU-145 prostate cancer cells were treated with 1 or 10 μM GSK2636771 for up to 48 hours and probed with the indicated antibodies
Supplementary Table S4: Hazard ratios (HR) and confidence intervals (CI) for overall survival (OS) using the two CTC variables and absolute CTC numbers before therapy from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Changes of CTC numbers in the total study cohort or in any of the different subgroups were not related to OS.
Supplementary Table S1: Circulating tumor cells (CTCs) and patient characteristics before and after neoadjuvant therapy (NT) from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Detection of CTCs associated with patient and tumor characteristics for both time points is listed. There was no significant correlation of {greater than or equal to}1CTC or {greater than or equal to}2CTCs to any of these parameters.
Supplementary Figure S3 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Supplementary Figure S3: Kaplan Meier plots for disease-free (DFS) and overall survival (OS) according to CTC detection after NT. (A, B) DFS, analysis of patients with HER2-positive tumors (A) and of patients with triple negative tumors (B) at cut-off {greater than or equal to}2 CTCs/7.5 mL, (C, D) OS, analysis of patients with HER2-positive tumors (C) and of patients with triple negative tumors (D) at cut-off {greater than or equal to}2 CTCs/7.5 mL.
Supplementary Figure S1 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Authors: Riethdorf Sabine , Müller Volkmar , Loibl Sibylle , Nekljudova Valentina , Weber Karsten , Huober Jens , Fehm Tanja , Schrader Iris , Hilfrich Jörn , Holms Frank , Tesch Hans , Schem Christian , von Minckwitz Gunter , Untch Michael , Pantel Klaus
Published: April 2023

Supplementary Figure S1: Kaplan Meier plots for disease-free (DFS) and overall survival (OS) according CTC detection after NT. (A, B) DFS, analysis of the whole patient cohort at CTC cut-offs {greater than or equal to}1 (A) and {greater than or equal to}2 (B) CTCs/7.5 mL blood, (C, D) OS, analysis of the whole patient cohort at CTC cut-offs {greater than or equal to}1 (E) and {greater than or equal to}2 (F) CTCs/7.5 mL blood.
Supplemental Figures and tables from The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
Authors: Cascone Tina , Xu Li , Lin Heather Y. , Liu Wenbin , Tran Hai T. , Liu Yuan , Howells Kathryn , Haddad Vincent , Hanrahan Emer , Nilsson Monique B. , Cortez Maria A. , Giri Uma , Kadara Humam , Saigal Babita , Park Yun-Yong , Peng Weiyi , Lee Ju-Seog , Ryan Anderson J. , Jüergensmeier Juliane M. , Herbst Roy S. , Wang Jing , Langley Robert R. , Wistuba Ignacio I. , Lee Jack J. , Heymach John V.
Published: April 2023

Supplemental Figures and Tables
Figure S6 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

The heat map of autophagy related genes in pictilisib (PIC), cisplatin (CIS) and combination (COM) resistant tumors of PDX BL0269 model
Table S2 from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

Tandem mass spectrometry parameter for targeted steroids and internal standards (IS).
Supplementary Data from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

Figure legend
Figure S3 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

Analysis of survival curves, tumor volumes and body weights
Figure S2 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

Ki67 and cleaved caspase 3 expression in BL0269 tumors
Supplementary Data Figure 3 from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

Immunohistochemistry staining of xenograft with 17βHSD2 and Ki67.
Figure S6 from In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Authors: Leung Ada W.Y. , Veinotte Chansey J. , Melong Nicole , Oh Min Hee , Chen Kent , Enfield Katey S.S. , Backstrom Ian , Warburton Corinna , Yapp Donald , Berman Jason N. , Bally Marcel B. , Lockwood William W.
Published: April 2023

PAPSS1 expression is associated with copy number status and is lower in lung adenocarcinoma compared to squamous cell carcinoma
Table S2 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Authors: Joseph Richard W. , Elassaiss-Schaap Jeroen , Kefford Richard , Hwu Wen-Jen , Wolchok Jedd D. , Joshua Anthony M. , Ribas Antoni , Hodi F. Stephen , Hamid Omid , Robert Caroline , Daud Adil , Dronca Roxana , Hersey Peter , Weber Jeffrey S. , Patnaik Amita , de Alwis Dinesh P. , Perrone Andrea , Zhang Jin , Kang S. Peter , Ebbinghaus Scot , Anderson Keaven M. , Gangadhar Tara C.
Published: April 2023

Supplemental Table
Figure S4 from In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Authors: Leung Ada W.Y. , Veinotte Chansey J. , Melong Nicole , Oh Min Hee , Chen Kent , Enfield Katey S.S. , Backstrom Ian , Warburton Corinna , Yapp Donald , Berman Jason N. , Bally Marcel B. , Lockwood William W.
Published: April 2023

Low-dose cisplatin is associated with decreased cell number in PAPSS1-silenced A549 spheroids but not in negative controls
Figure S2 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Authors: Joseph Richard W. , Elassaiss-Schaap Jeroen , Kefford Richard , Hwu Wen-Jen , Wolchok Jedd D. , Joshua Anthony M. , Ribas Antoni , Hodi F. Stephen , Hamid Omid , Robert Caroline , Daud Adil , Dronca Roxana , Hersey Peter , Weber Jeffrey S. , Patnaik Amita , de Alwis Dinesh P. , Perrone Andrea , Zhang Jin , Kang S. Peter , Ebbinghaus Scot , Anderson Keaven M. , Gangadhar Tara C.
Published: April 2023

Supplemental Figure
Figure S2 from In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Authors: Leung Ada W.Y. , Veinotte Chansey J. , Melong Nicole , Oh Min Hee , Chen Kent , Enfield Katey S.S. , Backstrom Ian , Warburton Corinna , Yapp Donald , Berman Jason N. , Bally Marcel B. , Lockwood William W.
Published: April 2023

Association between PAPSS1 expression and major driver mutation in lung adenocarcinoma
Figure Legends from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Authors: Joseph Richard W. , Elassaiss-Schaap Jeroen , Kefford Richard , Hwu Wen-Jen , Wolchok Jedd D. , Joshua Anthony M. , Ribas Antoni , Hodi F. Stephen , Hamid Omid , Robert Caroline , Daud Adil , Dronca Roxana , Hersey Peter , Weber Jeffrey S. , Patnaik Amita , de Alwis Dinesh P. , Perrone Andrea , Zhang Jin , Kang S. Peter , Ebbinghaus Scot , Anderson Keaven M. , Gangadhar Tara C.
Published: April 2023

Figure legends for supplemental figures
Supplementary Table S4 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Table S4. Focal copy number aberrations detected in the relapse samples
Supplementary figure S1 from 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Authors: D'Huyvetter Matthias , De Vos Jens , Xavier Catarina , Pruszynski Marek , Sterckx Yann G.J. , Massa Sam , Raes Geert , Caveliers Vicky , Zalutsky Michael R. , Lahoutte Tony , Devoogdt Nick
Published: April 2023

Supplementary figure S1 details the HER2-epitope recognized by 2Rs15d compared to those reported for other described HER2-binders and a view of HER2-Ãƒâ€šÃ,â­2Rs15d interactions.
Supplementary Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT
Authors: Elmi Azadeh , Makvandi Mehran , Weng Chi-Chang , Hou Catherine , Clark Amy S. , Mach Robert H. , Mankoff David A.
Published: April 2023

Supplementary Tables and Figures
Supplementary Methods from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

PDF file containing the Supplementary Methods and Supplementary References.
Table S4 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Table 4 | Clinicopathological characteristics (n=70 patients).
Supplementary Figure S2 from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

Supplementary Fig. S2: Repertoire of somatic mutations found in the biopsies of primary breast cancers and their metastatic lesions in the nine treatment-naÃ¯ve patients with de novo synchronous metastatic breast cancer. (A) Heatmaps indicate the cancer cell fraction of somatic mutations as determined by ABSOLUTE (24) (blue, see color key) or their absence (grey) in each biopsy (frozen and FFPE where available). Clonal mutations are highlighted in orange boxes and mutations associated with the loss of the wild-type allele are indicated with a diagonal bar. Red, dark grey and light grey dots beneath the heatmap indicate the mutation pathogenicity according to the color key. Mutations affecting cancer genes (31-33) are indicated by orange dots. Cases are grouped according to their ER and HER2 status. (B) Barplots of the distribution of mutations (top) present and (bottom) clonal in the frozen and FFPE diagnostic biopsies of the paired primary tumors and the metastatic lesions, classified as likely pathogenic (cancer genes), likely pathogenic (other genes), of indeterminate pathogenicity, likely passenger and synonymous mutations from all patients. Comparisons between the groups of mutations of different pathogenicity were performed using Fisher's exact tests. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ns: not significant.
Supplementary Figure S1 from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

Supplementary Fig. S1: Genome plots of copy number alterations. Genome plots of (A) tumors subjected to both whole-exome sequencing and OncoScan for copy number profiling and (B) the primary tumors and their synchronous distant metastases for cases 1-4, 6 and 8. In the genome plots, segmented Log2 ratios (y-axis) were plotted according to their genomic positions (x-axis). Alternating blue and grey demarcate the chromosomes. In (A), agreement of copy number status was assessed using Cohen's weighted kappa statistic.
Table S3 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Authors: Mauge Laetitia , Mejean Arnaud , Fournier Laure , Pereira Helena , Etienne-Grimaldi Marie-Christine , Levionnois Emeline , Caty Armelle , Abadie-Lacourtoisie Sophie , Culine Stéphane , Le Moulec Sylvestre , Linassier Claude , Théodore Christine , Ravaud Alain , Albiges Laurence , Grine Abel , Tartour Eric , Milano Gérard , Gille Anne-Sophie , Verkarre Virginie , Helley Dominique , Oudard Stéphane
Published: April 2023

Adverse events occurring in >10% of patients
Supplementary Figure S1, S2 and S3 from A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
Authors: Romaniello Donatella , Mazzeo Luigi , Mancini Maicol , Marrocco Ilaria , Noronha Ashish , Kreitman Matthew , Srivastava Swati , Ghosh Soma , Lindzen Moshit , Salame Tomer Meir , Onn Amir , Bar Jair , Yarden Yosef
Published: April 2023

Supplementary Figure S1: When applied in vitro on NSCLC cells, the combination of cetuximab and trastuzumab up-regulates beta-galactosidase, a marker of cellular senescence. β-galactosidase (β-Gal) staining of PC9ER cells pre-treated for 15 days with cetuximab (20 μg/ml), trastuzumab (20 μg/ml), or the combination (2XmAbs; total, 20 μg/ml). Scale bar, 100 μm. The histogram shows statistical analysis of positively-stained cells (means {plus minus} S.D). *, p {less than or equal to} 0.05, **, p {less than or equal to} 0.01, ***, p {less than or equal to} 0.001 (one-way ANOVA and Tukey's test). Supplementary Figure S2: Animal treatment with the combination of antibodies and osimertinib downregulates EGFR and RTKs involved in resistance to TKIs. PC9ER cells (2X106 cells per animal) were subcutaneously grafted in the flanks of CD1-nu/nu mice. Tumor-bearing mice were randomized into groups, which were treated daily with osimertinib (1 mg/kg/dose; oral gavage), an antibody combination (2XmAbs, cetuximab and trastuzumab; 0.2 mg/mouse/intraperitoneal injection) or 2XmAbs plus osimertinib. Shown are immunoblots of tumor extracts isolated 3 days or one week after treatment initiation and probed for the indicated proteins. Extracts were isolated from two different mice. Signals were quantified and normalized (numbers below each lane). GAPDH was used as loading control. The locations of molecular weight markers are indicated. Supplementary Figure S3: Mixtures of either two or three monoclonal antibodies (2XmAbs or 3XmAbs) induce variable anti-tumor effects when applied alone, after emergence of resistance to osimertinib. PC9ER cells (2x106) were subcutaneously injected in the flanks of CD-1 nu/nu mice. Once tumors reached a volume of 300-600 mm3, mice were orally treated with osimertinib (1 mg/kg), once per day. Invariably, tumors regressed and thereafter relapsed. Once relapsing tumors reached their original volume, mice were randomized and injected intraperitoneally twice a week with either 3XmAbs (A) or with 2XmAbs (B), but no further treatment with osimertinib was continued. Note that each panel displays results obtained using one animal.
Figure S5 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Authors: Hariri Lida P. , Adams David C. , Applegate Matthew B. , Miller Alyssa J. , Roop Benjamin W. , Villiger Martin , Bouma Brett E. , Suter Melissa J.
Published: April 2023

Figure S5 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Figure S4 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Authors: Hariri Lida P. , Adams David C. , Applegate Matthew B. , Miller Alyssa J. , Roop Benjamin W. , Villiger Martin , Bouma Brett E. , Suter Melissa J.
Published: April 2023

Figure S4 from Distinguishing Tumor from Associated Fibrosis to Increase Diagnostic Biopsy Yield with Polarization-Sensitive Optical Coherence Tomography
Supplementary Data from Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
Authors: Drent Esther , Poels Renée , Ruiter Ruud , van de Donk Niels W.C.J. , Zweegman Sonja , Yuan Huipin , de Bruijn Joost , Sadelain Michel , Lokhorst Henk M. , Groen Richard W.J. , Mutis Tuna , Themeli Maria
Published: April 2023

Supplementary methods and data
Table S5 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Sequence of siRNAs and primers
Table S3 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Clinical characteristics in ALK-rearranged NSCLC based on integrin β3 mRNA expression level
Table S2 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Treatment information of patients who received crizotinib
Figure S3 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Combination therapy of ALK and β3 inhibitors shows promising results in vivo and in ALK-rearranged NSCLC
Figure S2 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Authors: Noh Ka-Won , Sohn Insuk , Song Ji-Young , Shin Hyun-Tae , Kim Yu-Jin , Jung Kyungsoo , Sung Minjung , Kim Mingi , An Sungbin , Han Joungho , Lee Se-Hoon , Lee Mi-Sook , Choi Yoon-La
Published: April 2023

Functional role and regulation of integrin β3 in ALK-rearranged cell lines
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Table S1, Table S2, Table S3, Table S4 from Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment
Authors: Kato Takuya , Noma Kazuhiro , Ohara Toshiaki , Kashima Hajime , Katsura Yuki , Sato Hiroaki , Komoto Satoshi , Katsube Ryoichi , Ninomiya Takayuki , Tazawa Hiroshi , Shirakawa Yasuhiro , Fujiwara Toshiyoshi
Published: April 2023

Supplementary Figure 1. Subgroup analysis of TILs in intra-tumoral tissues according to UICC Stage. Supplementary Figure 2. Correlation between CAFs and ratios of peri- to intra-tumoral of CD8+ or FoxP3+ TILs. Supplementary Figure 3. Quantification of cytokines secreted into cell culture supernatants. Supplementary Figure 4. Fibroblasts and cancer cells cooperate to promote the release of IL-6 in human-derived esophageal cancer cell line. Supplementary Figure 5. IL-6 suppresses tumor immunity of SCCVII subcutaneous tumors in C3H/HeJ mice. Supplementary Figure 6. Correlation between IL-6 staining and αSMA+ CAFs in human esophageal cancer specimens. Supplementary Figure 7. Correlation among αSMA+ CAFs, IL-6 and hypoxia conditions in human esophageal cancer specimens Supplementary Table 1. Correlation between CD8+ or FoxP3+ TILs and clinicopathological characteristics of esophageal cancer. Supplementary Table 2. Univariate analysis of pathologic features and tumorinfiltrating lymphocytes for OS and DFS in esophageal cancer. Supplementary Table 3. Univariate analysis of OS and DFS in the subgroups in intratumoral tissues. Supplementary Table 4. Multivariate analysis of CD8+ and FoxP3+ TILs for OS and DFS in esophageal cancer.
Table S1 from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

Summary of FCH and FACE Imaging
Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Supplementary Methods
Supplementary text from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

Supplementary Methods and Figure Legends
Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

(A) Individual replicates of data shown in Figure 6A. (B) Individual replicates of data from Figure 6D.
Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Authors: Pasch Cheri A. , Favreau Peter F. , Yueh Alexander E. , Babiarz Christopher P. , Gillette Amani A. , Sharick Joe T. , Karim Mohammad Rezaul , Nickel Kwangok P. , DeZeeuw Alyssa K. , Sprackling Carley M. , Emmerich Philip B. , DeStefanis Rebecca A. , Pitera Rosabella T. , Payne Susan N. , Korkos Demetra P. , Clipson Linda , Walsh Christine M. , Miller Devon , Carchman Evie H. , Burkard Mark E. , Lemmon Kayla K. , Matkowskyj Kristina A. , Newton Michael A. , Ong Irene M. , Bassetti Michael F. , Kimple Randall J. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Individual replicates for data shown in Figure 5B.
Figure S3 from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

[18F]FCH and [18F]FACE-PET images of LAM patient renal angiomyolipoma-derived tumor xenografts.
Figure S2 from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

[18F]FCH uptake in TSC2-deficient cells in vivo after 72-hr exposure to vehicle control (two representative mice).
Figure S1 from [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Authors: Verwer Eline E. , Kavanagh Taylor R. , Mischler William J. , Feng You , Takahashi Kazue , Wang Shuyan , Shoup Timothy M. , Neelamegam Ramesh , Yang Jing , Guehl Nicolas J. , Ran Chongzhao , Massefski Walter , Cui Ye , El-Chemaly Souheil , Sadow Peter M. , Oldham William M. , Kijewski Marie F. , El Fakhri Georges , Normandin Marc D. , Priolo Carmen
Published: April 2023

Suppression of [18F]FCH uptake by treatment with rapamycin in TSC2-deficient cells in vivo (representative mouse 2).
Supplementary Methods and Results from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Authors: Sharma Priyanka , López-Tarruella Sara , García-Saenz José Angel , Khan Qamar J. , Gómez Henry L. , Prat Aleix , Moreno Fernando , Jerez-Gilarranz Yolanda , Barnadas Agustí , Picornell Antoni C. , Monte-Millán María del , González-Rivera Milagros , Massarrah Tatiana , Pelaez-Lorenzo Beatriz , Palomero María Isabel , González del Val Ricardo , Cortés Javier , Fuentes-Rivera Hugo , Morales Denisse Bretel , Márquez-Rodas Iván , Perou Charles M. , Lehn Carolyn , Wang Yen Y. , Klemp Jennifer R. , Mammen Joshua V. , Wagner Jamie L. , Amin Amanda L. , O’Dea Anne P. , Heldstab Jaimie , Jensen Roy A. , Kimler Bruce F. , Godwin Andrew K. , Martín Miguel
Published: April 2023

Further description of patient population and exploratory analysis.
Table S5 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

DS Group Classification within Select Clinicopathologic Factors
Table S4 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Interaction Analysis of RT by DS
Supplementary Methods from Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
Authors: Lamano Jonathan B. , Lamano Jason Balquidera , Li Yuping D. , DiDomenico Joseph D. , Choy Winward , Veliceasa Dorina , Oyon Daniel E. , Fakurnejad Shayan , Ampie Leonel , Kesavabhotla Kartik , Kaur Rajwant , Kaur Gurvinder , Biyashev Dauren , Unruh Dusten J. , Horbinski Craig M. , James C. David , Parsa Andrew T. , Bloch Orin
Published: April 2023

Methods pertaining to experiments presented as supplementary figures.
Supplementary Data from Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
Authors: Lamano Jonathan B. , Lamano Jason Balquidera , Li Yuping D. , DiDomenico Joseph D. , Choy Winward , Veliceasa Dorina , Oyon Daniel E. , Fakurnejad Shayan , Ampie Leonel , Kesavabhotla Kartik , Kaur Rajwant , Kaur Gurvinder , Biyashev Dauren , Unruh Dusten J. , Horbinski Craig M. , James C. David , Parsa Andrew T. , Bloch Orin
Published: April 2023

Supplementary Figures S1-S7.
Table S1 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Biomarker Assay Methodology
Supplementary Tables from IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lenzen Alicia , Lauing Kristen L. , Qian Jun , Scholtens Denise M. , Gritsina Galina , Sun Xuebing , Liu Ye , Yu Fenglong , Gong Wenfeng , Liu Yong , Jiang Beibei , Tang Tristin , Patel Ricky , Platanias Leonidas C. , James C. David , Stupp Roger , Lukas Rimas V. , Binder David C. , Wainwright Derek A.
Published: April 2023

Supplementary tables and associated legends Supplementary Table 1. Antibodies utilized for flow cytometry. Supplementary Table 2. Primers utilized for RT-PCR analysis Supplementary Table 3. Survival after treatment with BGB-5777, radiotherapy and/or PD-1 blockade in the GL261 model of advanced GBM.
Supplemental Material from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

A biologic signature for breast ductal carcinoma in situâ€¨ to predict radiation therapy (RT) benefit and assess recurrence risk
Figure S4 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Figure S4. Multivariate Analysis of Clinicopathologic and Molecular Factors Excluding Patients with Positive Margins for 10 Year IBE Risk
Figure S2 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Figure S2. Biologic Signature Interrogates Comprehensive Set of Pathways.
Figure S1 from A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
Authors: Bremer Troy , Whitworth Pat W. , Patel Rakesh , Savala Jess , Barry Todd , Lyle Stephen , Leesman Glen , Linke Steven P. , Jirström Karin , Zhou Wenjing , Amini Rose-Marie , Wärnberg Fredrik
Published: April 2023

Figure S1. Study Population Diagram
Supplemental Figure Legends from Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model
Authors: Nguyen Ferro , Alferiev Ivan , Guan Peng , Guerrero David T. , Kolla Venkatadri , Moorthy Ganesh S. , Chorny Michael , Brodeur Garrett M.
Published: April 2023

Supplemental Figure Legends
Figure S8 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

In vivo tumor growth treated with PD-1 signal blockades in nude, CD4+ T cell or CD8+ T cell-depleted mice.
S1 from Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model
Authors: Nguyen Ferro , Alferiev Ivan , Guan Peng , Guerrero David T. , Kolla Venkatadri , Moorthy Ganesh S. , Chorny Michael , Brodeur Garrett M.
Published: April 2023

Supp Figure S1 Figure S1. SRB assay assessing efficacy of free SN-38 and SN38-TOA NP. A, Growth inhibition by SN38-TOA NPs is statistically significant for 4 nM at 72-h (p=0.0002), and 2 nM and 4 nM at 96-h (p<0.0001). B, Growth inhibition by free SN-38 is statistically significant for 2 nM and 4 nM at 72-h (p>0.0001) and 96-h (p>0.0001), and 1 nM at 96-h (p=0.0007). FD = free drug. NP = nanoparticles.
Figure S5 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

In vivo tumor growth in nude, CD4+ T cell or CD8+ T cell-depleted mice.
Supplementary Table S7 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Authors: Yan Yibing , Wongchenko Matthew J. , Robert Caroline , Larkin James , Ascierto Paolo A. , Dréno Brigitte , Maio Michele , Garbe Claus , Chapman Paul B. , Sosman Jeffrey A. , Shi Zhen , Koeppen Hartmut , Hsu Jessie J. , Chang Ilsung , Caro Ivor , Rooney Isabelle , McArthur Grant A. , Ribas Antoni
Published: April 2023

Supplementary Table S7 from Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma
Figure S10 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

In vitro PD-L1 and PD-L2 expressions by MC-38-L1KO and MC-38-L1KO-L2 treated with or without IFN-γ and in vivo tumor growth of those tumors.
Figure S1 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

In vitro PD-L1 expression in MC38, CT26-NY-ESO-1, B16-F10, Renca, CMS5a and A20 treated with or without IFN-α, IFN-β, IFN-γ, TNF-α, IL-2, IL-4, TGF-β1 or GM-CSF.
Supplementary Figure 7 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Authors: de Leeuw Renée , McNair Christopher , Schiewer Matthew J. , Neupane Neermala Poudel , Brand Lucas J. , Augello Michael A. , Li Zhen , Cheng Larry C. , Yoshida Akihiro , Courtney Sean M. , Hazard E. Starr , Hardiman Gary , Hussain Maha H. , Diehl J. Alan , Drake Justin M. , Kelly Wm. Kevin , Knudsen Karen E.
Published: April 2023

Cbioportal analyses
Supplementary Figure 5 from MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Authors: de Leeuw Renée , McNair Christopher , Schiewer Matthew J. , Neupane Neermala Poudel , Brand Lucas J. , Augello Michael A. , Li Zhen , Cheng Larry C. , Yoshida Akihiro , Courtney Sean M. , Hazard E. Starr , Hardiman Gary , Hussain Maha H. , Diehl J. Alan , Drake Justin M. , Kelly Wm. Kevin , Knudsen Karen E.
Published: April 2023

LAPC4 aggressive phenotypes
Suppl. Figure S5 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Authors: Bahcall Magda , Awad Mark M. , Sholl Lynette M. , Wilson Frederick H. , Xu Man , Wang Stephen , Palakurthi Sangeetha , Choi Jihyun , Ivanova Elena V. , Leonardi Giulia C. , Ulrich Bryan C. , Paweletz Cloud P. , Kirschmeier Paul T. , Watanabe Masayuki , Baba Hideo , Nishino Mizuki , Nagy Rebecca J. , Lanman Richard B. , Capelletti Marzia , Chambers Emily S. , Redig Amanda J. , VanderLaan Paul A. , Costa Daniel B. , Imamura Yu , Jänne Pasi A.
Published: April 2023

DFCI358 patient-derived xenografts retain KRAS amplification